Added to YB: 2026-09-09
Pitch date: 2026-09-04
GSK [bullish]
GSK plc
-2.07%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 74.0B
Pitch Price
GBP 18.34
Price Target
N/A
Dividend
3.90%
EV/EBITDA
8.05
P/E
15.67
EV/Sales
2.67
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 4/9/2026 - GSK – Pipeline progress
GSK (update): GSK’s R&D pipeline rebuilding is making further progress, with its mRNA seasonal-flu vaccine advancing to Phase III this month after producing higher immune responses than standard-dose vaccines in younger adults and high-dose vaccines in older adults. With one billion flu cases annually, there is a clear commercial opportunity if development goes well, yet the shares trade at just 9.3x consensus 2028 earnings and yield 4.2%.
Read full article (1 min)